Sporadic Creutzfeldt-Jakob Disease After Receiving the Second Dose of Pfizer-BioNTech COVID-19 Vaccine

Andrea J. Folds
HCA Healthcare, andrea.folds@hcahealthcare.com

Melanie-Belle Ullrich
HCA Healthcare, melaniebelle.ullrich@hcahealthcare.com

Sann Htoo
HCA Healthcare, saan.htoo@hcahealthcare.com

Anjeza Chukus
HCA Healthcare, anjeza.chukus@hcahealthcare.com

Follow this and additional works at: https://scholarlycommons.hcahealthcare.com/internal-medicine

Part of the Internal Medicine Commons, and the Nervous System Diseases Commons

Recommended Citation
https://scholarlycommons.hcahealthcare.com/internal-medicine/420

This Poster is brought to you for free and open access by the Research & Publications at Scholarly Commons. It has been accepted for inclusion in Internal Medicine by an authorized administrator of Scholarly Commons.
Sporadic Creutzfeldt-Jakob Disease After Receiving the Second Dose of Pfizer-BioNTech COVID-19 Vaccine

Andrea J. Folds MD,1,2, Melanie-Belle Ulrich MD,1,2, Sann Y. Htoo MD, Anjeza Chukus MD,1,2
1. HCA Healthcare, Nashville, TN
2. Department of Internal Medicine, HCA Healthcare Aventura Hospital

Abstract

- Human prion disease is a rare, highly progressive neurodegenerative disease that is ultimately fatal.
- The majority of cases occur sporadically, although some may be genetic or acquired.
- Here, we highlight a case of a 64-year-old woman who presents with rapidly declining memory loss, behavioral changes, headaches, and gait disturbance approximately one week following administration of the second dose of the novel Pfizer-BioNTech messenger ribonucleic acid (mRNA) COVID-19 vaccine.
- After extensive investigation, conclusive evidence identified the fatal diagnosis of sporadic Creutzfeldt-Jakob disease.

Introduction

Human prion diseases were first described in the early 1920s and are delineated into three categories: sporadic, inherited, or acquired by way of infection. Of the sporadic type, there are Creutzfeldt-Jakob disease (CJD), fatal insomnia, and variable protease-sensitive prionopathy. Approximately 90% of cases of prion disease are sporadic CJD, which can be further divided into five subtypes based on clinical features, histological findings on autopsy, and molecular structure of the abnormal protein [1]. The incidence of sCJD is very rare, approximately 1-2 cases per one million per population. In the case presented herein, the plausibility of the Pfizer-BioNTech COVID-19 vaccine triggering sCJD is explored.

Case

- A 64-year-old woman with a past medical history of bipolar disorder and anxiety presents with rapidly progressive dementia, behavioral changes, headaches, and gait disturbance approximately one week after receiving the second dose of the Pfizer-BioNTech COVID-19 vaccine.
- Physical exam was essentially unremarkable except for confusion and significant distress regarding her condition.
- Initial labs, toxicology screening, and imaging were unremarkable except for a mildly increased white blood cell count.
- Psychiatry and neurology were consulted.
- Magnetic resonance (MR) imaging of the brain showed cortical diffusion restriction involving the bilateral frontal lobes, bilateral parietal lobes, and paramedian bilateral occipital lobes.
- Lumbar puncture: positive via the newest, highest sensitive real-time quaking-induced conversion (RT-QuIC) testing.
- T-tau protein measured at 38,979 (reference < 0-1,149).
- 14-3-3 protein was positive, neuron-specific enolase resulted at 16.3 (reference < 8.9).
- Exhibiting progressively worsening pyramidal and extrapyramidal symptoms, as well as akinetic mutism.
- Based on the Center for Disease Control and Prevention’s diagnostic criteria, the findings place her case as probable sporadic CJD with a definitive diagnosis to be made by a proper autopsy with neuropathological studies.

References


Discussion

- Normal prion protein is converted into an infectious, auto-enzymatic protein that aggregates in the brain tissue destroying neuronal cells leading to extensive neurodegeneration.
- Human prion protein (PrP), is encoded by the PrP gene, PrNP, which is located on the short arm of chromosome 20.
- Conversion to the diseased prion protein, termed PrPSc, is determined by PRNP polymorphism involving methionine (Met) or valine (Val) at codon 129 and prion strain (type 1 PrPSc or type 2 PrPSc).
- Etiology has been thought to be a mostly sporadic disease with no known specific cause.
- Retrospective case-control study in the United Kingdom found that all sporadic Creutzfeldt-Jakob disease (sCJD) cases from 1990 - 1998 lived close together, suggesting plausible precipitating factor.
- Various portions of the COVID-19 mRNA Pfizer-BioNTech vaccine have a high affinity for cytoplasmic proteins such as TAR DNA binding proteins (TDP-43) and Fused in Sarcoma (FUS).
- Spike protein, which is translated by the mRNA, can increase intracellular zinc, which has been shown to cause the conversion of TDP-43 into its pathological prion.
- Kuo et.al demonstrated how TDP-43 binds to mRNA transcripts with long UG-repeats.
- Pfizer-BioNTech’s COVID-19 vaccine contains many of these specific sequences.
- Tetz and Tetz identified a prion-like domain found in the receptor-binding domain of the S1 region of the SARS-CoV-2 spike protein.
- A case reported a previously healthy 60-year-old man who developed sudden onset sCJD with concurrent onset of symptoms of COVID-19.
- Case of a patient with sCJD whom also had positive serum neuronal antibodies to the voltage-gated potassium channel complex (VGK complex) and glycine receptor (GlyR) antibodies, suggesting a possible auto-immune mechanism.